Epigenetics, published by Taylor & Francis Inc, is a leading journal in the fields of Cancer Research, Medicine (miscellaneous), and Molecular Biology. With an ISSN of 1559-2294 and an E-ISSN of 1559-2308, this journal has been paving the way for groundbreaking research since its inception in 2006, and it continues to play a crucial role in advancing our understanding of epigenetic mechanisms and their implications in health and disease. The journal is highly regarded, ranking in the Q1 category for Medicine and Q2 for both Cancer Research and Molecular Biology according to the 2023 category quartiles. Researchers and professionals in the field will find invaluable insights and innovative studies within its pages, making it an essential resource for those engaged in cutting-edge research. Although the journal is not open access, it encourages a comprehensive understanding through high-quality peer-reviewed content. With its creative exploration of the epigenetic landscape, Epigenetics serves as a vital platform for the sharing of knowledge that could lead to breakthroughs in treatments and therapies.

RNA Biology is a premier journal published by Taylor & Francis Inc, focusing on the intricate and evolving field of RNA research. With an ISSN of 1547-6286 and E-ISSN of 1555-8584, this journal has established itself as an essential resource for professionals, researchers, and students engaged in both molecular and cell biology. Recognized in the 2023 quartile rankings, RNA Biology holds a distinguished Q1 category in Molecular Biology and a Q2 category in Cell Biology, indicative of its significant impact and reputation within the scientific community. The journal emphasizes the importance of RNA in various biological processes, highlighting both fundamental and applied aspects, which is crucial for advancing our understanding of gene expression and regulation. With a strong Scopus ranking, including Rank #105/410 in Molecular Biology and Rank #83/285 in Cell Biology, RNA Biology is not just a publication but a vital platform for sharing groundbreaking findings and insights into RNA research. With a convergence that spans from 2004 to 2024, the journal promises to continue its legacy of excellence in disseminating important discoveries in RNA science, contributing richly to ongoing scientific dialogue and innovation.

NUCLEIC ACIDS RESEARCH, published by Oxford University Press, is a premier peer-reviewed journal in the field of genetics, holding a prestigious Q1 ranking in this domain as of 2023. Since its inception in 1974 and with a converged publication horizon extending to 2024, this journal has established itself as a vital resource for researchers and professionals interested in the molecular aspects of nucleic acids, encompassing DNA and RNA studies as well as their implications in biochemistry and molecular biology. With an impressive Scopus rank of #6 out of 347 in Genetics, this journal is positioned in the 98th percentile among its peers, highlighting its significant impact and relevance in the scientific community. As an open access journal since 2005, NUCLEIC ACIDS RESEARCH ensures wide dissemination of knowledge, promoting collaborative advancements in genetic research. For those looking to stay at the forefront of nucleic acid research, this journal remains an essential publication for accessing cutting-edge findings and innovative methodologies in the field.

Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.

GENE, an esteemed journal published by Elsevier, serves as a vital resource for researchers and professionals in the fields of genetics and medicine. With an ISSN of 0378-1119 and an E-ISSN of 1879-0038, this scholarly journal has been at the forefront of genetic research since its inception in 1976 and is set to continue until 2025. Situated in the Netherlands, GENE is recognized for its significant contributions, reflected in its Q2 ranking in both Genetics and Miscellaneous Medicine categories for 2023. This positioning within the Scopus rankings demonstrates its impact and relevance in a competitive field, where it holds the rank of #129 out of 347 in Genetics, placing it within the 62nd percentile. Although it does not offer open access options, GENE provides invaluable insight into contemporary genetic research, thereby fostering academic discussions and advancements. Researchers, professionals, and students alike will find GENE an essential platform for disseminating knowledge and exploring innovative developments in genetics and associated sciences.

CELL BIOLOGY AND TOXICOLOGY, published by SPRINGER, stands as a vital journal within the realms of cell biology and toxicology, boasting an impressive 2023 Q1 ranking in its fields, alongside robust Scopus rankings placing it in the top 11th percentile for Toxicology and the 22nd for Health, Toxicology and Mutagenesis. With an ISSN of 0742-2091 and an E-ISSN of 1573-6822, the journal has been a cornerstone of scientific discourse since its inception in 1984, and will continue to converge innovative research until 2024. The journal focuses on the interplay between cellular mechanisms and toxicological implications, making it an essential resource for researchers, healthcare professionals, and students keen on advancing their understanding of these critical areas. Although it does not offer open access, its high impact and prestigious standing ensure that its publications reach a wide audience dedicated to significant advancements in the life sciences.

DNA AND CELL BIOLOGY, published by Mary Ann Liebert, Inc, is a distinguished journal in the realms of cell biology, genetics, and molecular biology, holding a notable position in its Q3 and Q2 quartile rankings across multiple academic categories as of 2023. With an ISSN of 1044-5498 and an E-ISSN of 1557-7430, this journal has been a pivotal platform for the dissemination of cutting-edge research since its inception in 1990, extending its coverage through 2024. Situated in the United States, the journal offers high-quality peer-reviewed articles, exploring significant advancements in biological sciences while fostering interdisciplinary collaborations within the research community. Though it currently does not offer open access, subscribed institutions and individual readers benefit from its rich repository of knowledge. The journal's rigorous standards and impactful content make it an essential resource for researchers, professionals, and students alike, aiming to stay at the forefront of discoveries influencing DNA and cellular dynamics.

MOLECULAR BIOLOGY, published by PLEIADES PUBLISHING INC, serves as a vital repository for the dissemination of innovative research within the fields of biochemistry, genetics, and molecular biology. With an ISSN of 0026-8933 and an E-ISSN of 1608-3245, this journal has been a mainstay in the scientific community since its inception, embracing its deep historical roots from 1971 to the present. Recognized for its qualitative contributions, MOLECULAR BIOLOGY is ranked in the Q3 quartile for Biophysics and Q4 for Structural Biology, placing it among select journals in its domain. Researchers and students alike benefit from its rigorous peer-reviewed articles, which focus on all aspects of molecular mechanisms and interactions. The journal's inclusion in prestigious databases underlines its commitment to academic excellence. The editorial board is dedicated to fostering the sharing of influential findings, making it an essential resource for advancing knowledge and innovation in molecular biology.

Epigenomics is a leading journal in the realms of Cancer Research and Genetics, published by Future Medicine Ltd in the United Kingdom. With an ISSN of 1750-1911 and an E-ISSN of 1750-192X, the journal has been an integral part of the scientific community since its inception in 2009, and is set to converge its impactful research publications through 2024. The journal occupies a significant position in its category quartiles as evidenced by its ranking—Q3 in Cancer Research and Q2 in Genetics as of 2023. With Scopus rankings of #138/347 in Genetics and #113/230 in Cancer Research, it demonstrates scholarly excellence and is recognized for its contributions to understanding the role of epigenetic modifications in health and disease. While Epigenomics operates under traditional subscription models, it remains a vital resource for researchers, professionals, and students eager to explore the complex interplay between genes and the epigenome. The journal's innovative approach to epigenetics and its impact on cancer research makes it essential reading for those at the forefront of biomedical research.

CELLULAR SIGNALLING, published by Elsevier Science Inc, is a premier journal within the realm of Cell Biology, boasting an impressive Q2 category ranking as of 2023. With an ISSN of 0898-6568 and an E-ISSN of 1873-3913, the journal has established itself as a critical platform for advancing the understanding of cellular mechanisms and signal transduction pathways since its inception in 1989. Covering a vast array of topics in Biochemistry, Genetics, and Molecular Biology, it ranks notably at 87 out of 285 in the Scopus list, placing it in the 69th percentile among its peers. The journal serves as an invaluable resource for researchers, professionals, and students seeking high-quality, impactful studies that drive forward the field of cellular biology. While it operates under traditional subscription access, its highlights include rigorous peer-reviewed articles, reviews, and insights that continue to shape current scientific discourse.